Food and Drug Administration Commissioner Scott Gottlieb, M.D., yesterday shared an update on the agency’s work to mitigate shortages of intravenous drugs, shorten supply disruptions and better predict vulnerabilities. Among other actions, Gottlieb said FDA is “evaluating our current authorities to see what more we can do to better mitigate and prevent shortages, including receiving additional, key information from industry when they notify the agency about a possible shortage and identifying all establishments where manufacturing is performed associated with listed drugs and the type of operation performed at each such establishment.” In addition, Gottlieb said the agency could ask Congress to expand its authority to require manufacturers to conduct risk assessments “to identify the vulnerabilities in their drug supply, including vulnerabilities that could cause a shortage, and establish risk mitigation plans to address those risks.”
 

Related News Articles

Headline
The AHA, American Medical Association, American Society of Anesthesiologists, American Society of Health-System Pharmacists, and Association for Clinical…
Headline
Reps. Scott Peters, D-Calif., Eliot Engel, D-N.Y., Brett Guthrie, R-KY, Anna Eshoo, D-Calif., Richard Hudson, R-N.C., Michael McCaul, R-Texas, Kurt Schrader, D…
Headline
The Food and Drug Administration today released a proposed rule that would allow states and other non-federal government entities to establish programs to…
Headline
The Food and Drug Administration yesterday approved the first test to use next generation sequencing technology to detect HIV drug-resistance mutations in…
Headline
Pictured, from left to right: Peter Adamson, chair of the Children’s Oncology Group at the Children’s Hospital of Philadelphia; Brian Marden, chief…
Headline
The AHA, American Society of Anesthesiologists, American Society of Clinical Oncology, American Society of Health-System Pharmacists and Institute for Safe…